



Cite this: *Chem. Sci.*, 2023, **14**, 5728

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 10th April 2023
 Accepted 3rd May 2023

DOI: 10.1039/d3sc01868g
rsc.li/chemical-science


Introduction

Among the vast array of pharmaceutical compounds, peptides have emerged as powerful candidates for drug development.¹ Since the first medical use of insulin in 1921,¹ the field of peptide-based drugs has progressively grown, currently accounting for 5% of the global pharmaceutical market and with approvals steadily increasing. Many therapeutic peptides operate by binding to cell membrane components with high affinity, triggering specific intracellular effects.² In particular, antimicrobial peptides are emerging as a promising alternative to combat antimicrobial drug-resistance.³ In this regard, fluorogenic labeling of peptides which enables real-time imaging studies is of key importance to analyze their functional mechanism and to develop new therapeutics.⁴ While a variety of chemical motifs have been employed in the development of fluorescent probes, those emitting in the near-infrared (NIR) window (650–900 nm) are attracting particular attention, since they have the advantages of low autofluorescence of biomolecules as well as low toxicities due to light irradiation at relatively long excitation wavelengths.⁵ Nitrobenzodiazole (NBD) fluorescent dyes have been identified as powerful labeling tags because

of their small size, neutral character, cell permeability and large Stokes shifts.⁶ In addition, Vendrell and Lee recently reported NBD derivatives with NIR fluorescent properties.⁷ Examples of NBD labeling peptide and protein were reported, including the modification of nucleophilic cysteine or 3-amino-alanine residues (Scheme 1a and b).⁸ Despite remarkable progress, the introduction of NBD is hence largely limited to the nucleophilic

Previous studies of NBD-peptide conjugates


a) Schimer



b) Mazarguil



Late-stage NBD labeling via manganese-catalyzed C–H activation (this work)



⊕ Small size and neutral NBD scaffolds

⊕ Non-toxic manganese catalyst and mild reaction conditions

⊕ Chemodivergent Trp-NBD labeling via C–H activation

Scheme 1 Nucleophilic NBD labeling (a and b) versus manganese(II)-catalyzed NBD labeling of tryptophans.

^aInstitut für Organische und Biomolekulare Chemie, Georg-August-Universität Göttingen, Tammstraße 2, 37077, Göttingen, Germany. E-mail: lutz.ackermann@chemie.uni-goettingen.de

^bCentre for Inflammation Research, The University of Edinburgh, EH16 4TJ Edinburgh, UK. E-mail: marc.vendrell@ed.ac.uk

^cGerman Center for Cardiovascular Research (DZHK), Potsdamer Straße 58, 10785, Berlin, Germany

† Electronic supplementary information (ESI) available. See DOI: <https://doi.org/10.1039/d3sc01868g>

‡ These authors contributed equally to this work.



region, such as *N*-terminal groups, thiols or phenols using classical condensations or S_NAr type reactions.⁸

During the past decade, transition-metal-catalyzed C–H activation⁹ has surfaced as a transformative platform for the direct modification of peptides,¹⁰ with major contributions from Lavilla and Albericio,¹¹ Chen,¹² Wang,¹³ Shi,¹⁴ Yu,¹⁵ and Ackermann,¹⁶ among others.¹⁷ While significant progress has thereby been realized, molecular peptide labeling with NIR dyes has thus proven elusive. In sharp contrast, we now have identified a strategy to stitch tryptophan with NBD fluorophores *via* earth-abundant and non-toxic manganese(i)-catalyzed C–H activation,¹⁸ and applied this approach for real-time imaging by using a model peptide targeting bacterial cell membranes. This strategy has the power to facilitate structure–activity relationship studies of fluorescent probes with NBD, since there is no report of direct conjugation to tryptophan residues.

Result and discussion

We initiated our studies by proving difficult reaction conditions with tryptophan derivative **1** and 4-ethynyl-7-nitrobenzoxadiazole (**2**) (Table 1). After optimization of reaction parameters (see details in the ESI Table S1†), we obtained the desired C_2 functionalized product **3** in 95% yield in the presence of $MnBr(CO)_5$, KOAc, and BPh_3 (entry 1). Subsequently, we investigated the efficiency of other catalysts, such as $ReBr(CO)_5$, which delivered product **3** only in moderate yield (entry 2). Likewise, significantly decreased catalytic activity was observed with $Mn_2(CO)_{10}$ (entry 3). It is noteworthy that $Pd(OAc)_2$, $[RuCl_2(p\text{-cymene})]_2$, $[RhCp^*Cl_2]_2$, and $Co(OAc)_2$ showed no catalytic efficiencies (entries 4–7), indicating the

challenges associated with a chemo-selective NBD labeling. Interestingly, the manganese(i)-catalyzed C–H activation proceeded even at physiological temperature of 37 °C, delivering the desired product **3** in 78% yield (entry 8). Control experiments showed that manganese(i) catalyst, KOAc, and BPh_3 were essential for the reaction (entries 9–11).

With the optimized reaction conditions for NBD-based fluorescence labeling in hand, we explored the generality of the Mn(i) catalysis (Scheme 2). The Mn(i) catalysis tolerated various tryptophans with Ac and Alloc groups at the *N*-terminus, generating the desired products **5** and **6** in good yields with complete diastereo-*E*-selectivities. It must be noted that benzyl esters at the C-terminus of tryptophan was compatible with our catalytic reaction conditions, offering the potential for further derivatization into peptides (**4**). In addition, NBD-alkynes bearing a different chalcogen or electron-donating group could also be converted using our strategy (**8** and **9**).


Subsequently, we investigated the late-stage diversification of dipeptides. An outstanding chemo-selectivity was demonstrated by the complete tolerance of sensitive functional groups on the amino acid side chains. For instance, successful transformation of dipeptides with alkyl side chains were observed without epimerization (**10**, **11**, **16**, and **18**). Furthermore, the presence of unprotected primary and secondary alcohols or phenols did not interfere with the reaction, furnishing the desired products **12**, **13**, and **15** in good yields. Oxidation-sensitive groups found in methionine and protected cysteine were also tolerated (**17** and **20**) (Scheme 3).

Interestingly, dipeptides containing an unmodified indole moiety delivered the desired alkenylated product with excellent site selectivity (**14**). Lastly, good tolerance of substituted amines and unprotected amides showed the robustness of these reaction conditions (**19** and **21**). Triggered by the versatility of our C–H alkenylation regime, we expanded to more challenging tri-

Table 1 Optimization of the reaction conditions^a


Entry	Deviation from the standard conditions	Yield ^c (%)
1	None ^b	95
2	$ReBr(CO)_5$ in place of $MnBr(CO)_5$	60
3	$Mn_2(CO)_{10}$ in place of $MnBr(CO)_5$	Trace
4	$Pd(OAc)_2$ in place of $MnBr(CO)_5$	—
5	$[RuCl_2(p\text{-cymene})]_2$ in place of $MnBr(CO)_5$	—
6	$[RhCp^*Cl_2]_2$ in place of $MnBr(CO)_5$	—
7	$Co(OAc)_2$ in place of $MnBr(CO)_5$	—
8	At 37 °C	78
9	Without $MnBr(CO)_5$	—
10	Without BPh_3	4
11	Without KOAc	Trace

^a DCE: 1,2-dichloroethane. ^b Standard conditions: **1** (0.10 mmol), **2** (0.15 mmol), $MnBr(CO)_5$ (20 mol%), BPh_3 (40 mol%), KOAc (40 mol%), DCE (1.0 mL), 60 °C, 18 h. ^c Isolated yields.



Scheme 2 NBD labeling of tryptophans.





Scheme 3 Robustness of $C(sp^2)$ -H alkenylation. [a] 0.050 mmol of peptide, 40 mol% of $MnBr(CO)_5$, 80 mol% of $KOAc$ and BPh_3 , 0.10 mmol of 2, and 1.0 mL of DCE were used. [b] 0.050 mmol of peptide, 0.050 mmol of $MnBr(CO)_5$, 0.10 mmol of $KOAc$ and BPh_3 , 0.15 mmol of 2, and 1.0 mL of DCE were used. Reaction time: 6 h.

and tetra-peptides which were converted in a site-, regio-, chemo-, and diastereo-*E*-selective manner (22–31). The robustness of our $Mn(i)$ catalysis was also highlighted with the

successful transformation of aspartic or glutamic acid-containing substrates (23, 25–27, and 30), which are known to cyclize into 5- or 6-membered amides.¹⁹ In addition, the side






Fig. 1 (a) Absorbance (dashed lines) and emission (solid lines) spectra of the amino acids 3 and 8. (b) Fluorescence emission spectra of the amino acids 3 and 8 ($10 \mu\text{M}$) in water (black line) and in dioxane (red line). λ_{exc} : 480 nm (3) and 450 nm (8). Relative fluorescence quantum yields were determined using fluorescein as a standard: 0.7% for compound 3, 4.7% for compound 8. (c) Synthetic scheme for the preparation of bacterial-binding peptide 32 with amino acid 8. (d) Schematic illustration of the fluorescence activation of peptide 32 in both Gram-positive and Gram-negative bacteria with the environmentally-sensitive amino acid 8 as the fluorophore. (e) Fluorescence and brightfield microscopy images of Gram-positive bacteria (top panel, *S. aureus*) and Gram-negative bacteria (bottom panel, *E. coli*) after labelling with compound 32 ($25 \mu\text{M}$). Scale bar: $10 \mu\text{m}$.

formation of dehydro-alanine derivatives was not observed, which can be formed in serine-containing substrates *via* β -elimination (28 and 31). It must be noted that a tetrapeptide containing a disulfide bond was also amenable to our Mn(i)-catalyzed labeling process (29).

Next, we examined the fluorescence properties of the oxygen and sulfur NBD-labeled tryptophan derivatives 3 and 8, revealing absorption maxima wavelengths at 522 nm and 496 nm, and emission maxima wavelengths in the NIR-I window (688 nm and 658 nm respectively, Fig. 1a). Notably, both labeled amino acids exhibited very large Stokes shifts over 150 nm. Another important consideration is that NBD is relatively small compared to previously reported NIR-emitting scaffolds, helping to potentially retain the biological activity of the native peptides. Considering the potential molecular rotor features of our NBD-labeled tryptophan analogues, we also compared the turn-on effect of the amino acids 3 and 8 (Fig. 1b). As anticipated, both amino acids exhibited remarkable turn-on fluorescence in dioxane compared to H_2O , with the S-containing compound 8 showing over 150-fold fluorescence increase in hydrophobic environments. Encouraged by the excellent fluorogenicity of the amino acid 8, we decided to use it for solid-phase peptide synthesis (SPPS) of the bacterial-targeting sequence 32 (Fig. 1c). This sequence is based on previous reports on cationic amphipathic peptides possessing both hydrophobic and hydrophilic regions, known to enable binding to the microbial cell envelope.²⁰ Compound 8 proved compatible with standard SPPS coupling agents (*e.g.*, Pyoxim) and cleavage conditions (*e.g.*, trifluoroacetic acid, TFA), and we

could successfully synthesize the labeled peptide 32 (Fig. 1c) in 4% yield and with high purities over 95%. Next, we exploited the turn-on features of peptide 32 for wash-free imaging of bacterial cells (Fig. 1d). First, we tested different concentrations of peptide 32 for imaging Gram-positive (*S. aureus*) and Gram-negative (*E. coli*) bacteria under fluorescence microscopy (Fig. S1†). Importantly, the environmental sensitivity of the NBD moiety allowed direct visualization of both bacterial cells without any additional steps or washing procedures (Fig. S2†). After optimization of the labeling protocol, we employed peptide 32 in confocal fluorescence microscopy for real-time and wash-free imaging of *S. aureus* and *E. coli* bacterial cultures with high signal-to-noise ratios (Fig. 1e). Altogether, these results confirm that the NBD moiety did not alter the bacterial-targeting ability of the peptide sequence and showcase the utility of this fluorescence labeling method for NIR wash-free imaging in live cells.

Conclusions

In summary, we have developed an unprecedent late-stage labeling strategy of structurally complex peptides with NIR-emitting dyes *via* C(sp^2)-H activation. Thereby, the assembly of fluorescent amino acids and peptides was achieved with excellent site-, chemo-, and diastereo-*E*-selectivity using an earth-abundant manganese(i) pre-catalyst of low toxicity. Furthermore, we identified that the NIR-labeled peptide 32 can be used for imaging of live bacteria and under wash-free conditions. Overall, this strategy features excellent properties



of NBD labeled amino acids and peptides, such as large Stokes shifts, NIR emission wavelengths, and excellent fluorogenicity for real time imaging in live cells.

Data availability

Data available from the authors upon reasonable request.

Author contributions

T. O., and L. A. conceived the project. T. O. and A. K. performed the synthetic experiments. L. M.-T. and V. C. performed imaging experiments. T. O., L. M.-T., M. V., and L. A. wrote the manuscript with contributions from all authors.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors gratefully acknowledge support from the DFG (Gottfried-Wilhelm-Leibniz award) and DZHK (PI at German Centre for Cardiovascular Research) to L. A., the European Union's Horizon 2020 research and innovation programme (Marie Skłodowska-Curie Grant Agreement No. 860762) to T. O. L. M.-T. acknowledges funding the Wellcome Trust Institutional Strategic Support Fund (ISSF) at the University of Edinburgh. M. V. acknowledges funding from an ERC Consolidator Grant (771443, DYNAFLUORS).

References

- (a) L. Wang, N. Wang, W. Zhang, X. Cheng, Z. Yan, G. Shao, X. Whang and abd C. Fu, *Signal Transduct Target Ther.*, 2022, **7**, 48; (b) M. Muttenthaler, G. F. King, D. J. Adams and P. F. Alewood, *Nat. Rev. Drug Discovery*, 2021, **20**, 309; (c) J. L. Lau and M. K. Dunn, *Bioorg. Med. Chem.*, 2018, **26**, 2700; (d) W. Chiangjong, S. Chutipongtanate and S. Hongeng, *Int. J. Oncol.*, 2020, **57**, 678.
- P. Hoppenz, S. Els-Heindl and A. G. Beck-Sickinger, *Front. Chem.*, 2020, **8**, 571.
- (a) B. H. Gan, J. Gaynord, S. M. Rowe, T. Deingruber and D. R. Spring, *Chem. Soc. Rev.*, 2021, **50**, 7820; (b) M. Rima, M. Rima, Z. Fajloun, J.-M. Sabatier, B. Bechinger and T. Naas, *Antibiotics*, 2021, **10**, 1095.
- (a) Z. Cheng, E. Kuru, A. Sachdeva and M. Vendrell, *Nat. Rev. Chem.*, 2020, **4**, 275; (b) M. Sameiro and T. Gonçalves, *Chem. Rev.*, 2009, **109**, 190.
- (a) Z. Guo, S. Park, J. Yoon and I. Shin, *Chem. Soc. Rev.*, 2014, **43**, 16; (b) A. L. Vahrmeijer, M. Hutteman, J. R. van der Vorst, C. J. H. van de Velde and J. V. Frangioni, *Nat. Rev. Clin. Oncol.*, 2013, **10**, 507.
- (a) S. Benson, A. Fernandez, N. D. Barth, F. de Moliner, M. H. Horrocks, C. S. Herrington, J. L. Abad, A. Delgado, L. Kelly, Z. Chang, Y. Feng, M. Nishiura, Y. Hori, K. Kikuchi and M. Vendrell, *Angew. Chem., Int. Ed.*, 2019, **58**, 6911; (b) D. R. Jenkinson, A. J. Cadby and S. Jones, *Chem.-Eur. J.*, 2017, **23**, 12585; (c) Y. Shen, Y. Zhang, X. Zhang, C. Zhang, L. Zhang, J. Jin, H. Li and S. Yao, *Anal. Methods*, 2014, **6**, 4797; (d) L. D. Lavis and R. T. Raines, *ACS Chem. Biol.*, 2008, **3**, 142.
- F. de Moliner, I. Biazruchka, K. Konsewicz, S. Benson, S. Singh, J.-S. Lee and M. Vendrell, *Front. Chem. Sci. Eng.*, 2022, **16**, 128.
- (a) S. Benson, F. de Moliner, A. Fernandez, E. Kuru, N. L. Asiimwe, J.-S. Lee, L. Hamilton, D. Sieger, I. R. Bravo, A. M. Elliot, Y. Feng and M. Vendrell, *Nat. Commun.*, 2021, **12**, 2369; (b) V. Verdoliva, G. Digilio, M. Saviano and S. D. Luca, *Catal. Sci. Technol.*, 2021, **11**, 1067; (c) A. R. Akram, N. Avlonitis, E. Scholefield, M. Vendrell, N. McDonald, T. Aslam, T. H. Craven, C. Gray, D. S. Collie, A. J. Fisher, P. A. Corris, T. Walsh, C. Haslett, M. Bradley and K. Dhaliwal, *Sci. Rep.*, 2019, **9**, 8422; (d) I. Dufau and H. Mazarguil, *Tetrahedron Lett.*, 2000, **41**, 6063; (e) N. C. Prices, M. Cohn and R. H. Schirmer, *J. Biol. Chem.*, 1975, **250**, 644; (f) P. B. Ghosh and M. W. Whitehouse, *Biochem. J.*, 1968, **108**, 155.
- For selected reviews on C–H activation, see: (a) P. Gandeepan and L. Ackermann, *Chem.*, 2018, **4**, 199; (b) Y. Wei, P. Hu, M. Zhang and W. Su, *Chem. Rev.*, 2017, **117**, 8864; (c) M. M. Lorion, K. Maindan, A. R. Kapdi and L. Ackermann, *Chem. Soc. Rev.*, 2017, **46**, 7399; (d) J. A. Leitch and C. G. Frost, *Chem. Soc. Rev.*, 2017, **46**, 7145; (e) J. He, M. Wasa, K. S. L. Chan, Q. Shao and J.-Q. Yu, *Chem. Rev.*, 2017, **117**, 8754; (f) Q.-Z. Zheng and N. Jiao, *Chem. Soc. Rev.*, 2016, **45**, 4590; (g) M. Moselage, J. Li and L. Ackermann, *ACS Catal.*, 2016, **6**, 498; (h) B. Ye and N. Cramer, *Acc. Chem. Res.*, 2015, **48**, 1308; (i) J. Wencel-Delord and F. Glorius, *Nat. Chem.*, 2013, **5**, 369; (j) G. Rouquet and N. Chatani, *Angew. Chem., Int. Ed.*, 2013, **52**, 11726; (k) S. R. Neufeldt and M. S. Sanford, *Acc. Chem. Res.*, 2012, **45**, 936; (l) L. McMurray, F. O'Hara and M. J. Gaunt, *Chem. Soc. Rev.*, 2011, **40**, 1885; (m) L. Ackermann, R. Vicente and A. R. Kapdi, *Angew. Chem., Int. Ed.*, 2009, **48**, 9792.
- (a) M. Jbara, S. K. Maity and A. Brik, *Angew. Chem., Int. Ed.*, 2017, **56**, 10644; (b) A. F. M. Noisier and M. A. Brimble, *Chem. Rev.*, 2014, **114**, 8775.
- Selected examples, see: (a) R. Subiros-Funosas, L. Mendive-Tapia, J. Sot, J. D. Pound, N. Barth, Y. Varela, F. M. Goni, M. Paterson, C. D. Gregory, F. Albericio, I. Dransfield, R. Lavilla and M. Vendrell, *Chem. Commun.*, 2017, **53**, 945; (b) S. Preciado, L. Mendive-Tapia, F. Albericio and R. Lavilla, *J. Org. Chem.*, 2013, **78**, 8129; (c) J. Ruiz-Rodríguez, F. Albericio and R. Lavilla, *Chem.-Eur. J.*, 2010, **16**, 1124.
- Selected examples, see: (a) X. Chen, F. Ye, X. Luo, X. Liu, J. Zhao, S. Wang, Q. Zhou, G. Chen and P. Wang, *J. Am. Chem. Soc.*, 2019, **141**, 18230; (b) X. Zhang, G. Lu, M. Sun, M. Mahankali, Y. Ma, M. Zhang, W. Hua, Y. Hu, Q. Wang, J. Chen, G. He, X. Qi, W. Shen, P. Liu and G. Chen, *Nat. Chem.*, 2018, **10**, 540; (c) G. He, B. Wang, W. A. Nack and G. Chen, *Acc. Chem. Res.*, 2016, **49**, 635; (d) B. Wang,



- W. A. Nack, G. He, S.-Y. Zhang and G. Chen, *Chem. Sci.*, 2014, **5**, 3952; (e) S.-Y. Zhang, Q. Li, G. He, W. A. Nack and G. Chen, *J. Am. Chem. Soc.*, 2013, **135**, 12135; (f) Y. Feng and G. Chen, *Angew. Chem., Int. Ed.*, 2010, **49**, 958.
- 13 (a) L. Liu, X. Fan, B. Wang, H. Deng, T. Wang, J. Zheng, J. Chen, Z. Shi and H. Wang, *Angew. Chem., Int. Ed.*, 2022, **61**, e2022061; (b) C. Cai, F. Wang, X. Xiao, W. Sheng, S. Liu, J. Chen, J. Zheng, R. Xie, Z. Bai and H. Wang, *Chem. Commun.*, 2022, **58**, 4861; (c) S. Liu, C. Cai, Z. Bai, W. Sheng, J. Tan and H. Wang, *Org. Lett.*, 2021, **23**, 2933; (d) T. Long, L. Liu, Y. Tao, W. Zhang, J. Quan, J. Zheng, J. D. Hegemann, M. Uesugi, W. Yao, H. Tian and H. Wang, *Angew. Chem., Int. Ed.*, 2021, **60**, 13414; (e) Z. Bai, Q. Chen, J. Gu, C. Cai, J. Zheng, W. Sheng, S. Yi, F. Liu and H. Wang, *ACS Catal.*, 2021, **11**, 15125; (f) Z. Bai, C. Cai, W. Sheng, Y. Ren and H. Wang, *Angew. Chem., Int. Ed.*, 2020, **59**, 14686.
- 14 (a) X.-S. Yin, W.-Y. Qi and B.-F. Shi, *Chem. Sci.*, 2021, **12**, 13137; (b) L. Liu, Y.-H. Liu and B.-F. Shi, *Chem. Sci.*, 2020, **11**, 290; (c) B.-B. Zhan, J. Fan, L. Jin and B.-F. Shi, *ACS Catal.*, 2019, **9**, 3298; (d) B. B. Zhan, Y. Li, J. W. Xu, X. L. Nie, J. Fan, L. Jin and B. F. Shi, *Angew. Chem., Int. Ed.*, 2018, **57**, 5858; (e) G. Liao, X.-S. Yin, K. Chen, Q. Zhang, S.-Q. Zhang and B.-F. Shi, *Nat. Commun.*, 2016, **7**, 12901; (f) K. Chen, X. Li, S.-Q. Zhang and B.-F. Shi, *Org. Chem. Front.*, 2016, **3**, 204; (g) K. Chen, S.-Q. Zhang, J.-W. Xu, F. Hu and B.-F. Shi, *Chem. Commun.*, 2014, **50**, 13924; (h) K. Chen and B. F. Shi, *Angew. Chem., Int. Ed.*, 2014, **53**, 11950; (i) K. Chen, F. Hu, S.-Q. Zhang and B.-F. Shi, *Chem. Sci.*, 2013, **4**, 3906.
- 15 (a) T. Liu, J. X. Qiao, M. A. Poss and J.-Q. Yu, *Angew. Chem., Int. Ed.*, 2017, **56**, 10924; (b) G. Chen, T. Shigenari, P. Jain, Z. Zhang, Z. Jin, J. He, S. Li, C. Mapelli, M. M. Miller, M. A. Poss, P. M. Scola, K.-S. Yeung and J.-Q. Yu, *J. Am. Chem. Soc.*, 2015, **137**, 3338; (c) J. He, S. Li, Y. Deng, H. Fu, B. N. Laforteza, J. E. Spangler, A. Homs and J.-Q. Yu, *Science*, 2014, **343**, 1216; (d) W. Gong, G. Zhang, T. Liu, R. Giri and J.-Q. Yu, *J. Am. Chem. Soc.*, 2014, **136**, 16940.
- 16 (a) X. Hou, N. Kaplaneris, B. Yuan, J. Frey, T. Ohyama, A. M. Messinis and L. Ackermann, *Chem. Sci.*, 2022, **13**, 3461; (b) N. Kaplaneris, J. Son, L. Mendive-Tapia, A. Kopp, N. D. Barth, I. Maksso, M. Vendrell and L. Ackermann, *Nat. Commun.*, 2021, **12**, 3389; (c) M. Stangier, A. M. Messinis, J. C. A. Oliveira, H. Yu and L. Ackermann, *Nat. Commun.*, 2021, **12**, 4736; (d) N. Kaplaneris, F. Kaltenhäuser, G. Sirvinskaite, S. Fan, T. D. Oliveira, L.-C. Conradi and L. Ackermann, *Sci. Adv.*, 2021, **7**, eabe6202; (e) W. Wang, J. Wu, R. Kuniyil, A. Kopp, R. N. Lima and L. Ackermann, *Chem.*, 2020, **6**, 3428; (f) J. Wu, N. Kaplaneris, S. Ni, F. Kaltenhäusera and L. Ackermann, *Chem. Sci.*, 2020, **11**, 6521; (g) A. Schischko, N. Kaplaneris, T. Rogge, G. Sirvinskaite, J. Son and L. Ackermann, *Nat. Commun.*, 2019, **10**, 3553; (h) W. Wang, P. Subramanian, O. Martinazzoli, J. Wu and L. Ackermann, *Chem.-Eur. J.*, 2019, **25**, 10585; (i) N. Kaplaneris, T. Rogge, R. Yin, H. Wang, G. Sirvinskaite and L. Ackermann, *Angew. Chem., Int. Ed.*, 2019, **58**, 3476; (j) M. M. Lorion, N. Kaplaneris, J. Son, R. Kuniyil and L. Ackermann, *Angew. Chem., Int. Ed.*, 2019, **58**, 1684; (k) W. Wang, M. M. Lorion, O. Martinazzoli and L. Ackermann, *Angew. Chem., Int. Ed.*, 2018, **57**, 10554; (l) M. Bauer, W. Wang, M. M. Lorion, C. Dong and L. Ackermann, *Angew. Chem., Int. Ed.*, 2018, **57**, 203; (m) H. Wang, M. M. Lorion and L. Ackermann, *Angew. Chem., Int. Ed.*, 2017, **56**, 6339; (n) A. Schischko, H. Ren, N. Kaplaneris and L. Ackermann, *Angew. Chem., Int. Ed.*, 2017, **56**, 1576; (o) Z. Ruan, N. Sauermann, E. Manoni and L. Ackermann, *Angew. Chem., Int. Ed.*, 2017, **56**, 3172; (p) Y. Zhu, M. Bauer and L. Ackermann, *Chem.-Eur. J.*, 2015, **21**, 9980; (q) Y. Zhu, M. Bauer, J. Ploog and L. Ackermann, *Chem.-Eur. J.*, 2014, **20**, 13099.
- 17 (a) X. Wang, S. Niu, L. Xu, C. Zhang, L. Meng, X. Zhang and D. Ma, *Org. Lett.*, 2017, **19**, 246; (b) M. San Segundo, I. Guerrero and A. Correa, *Org. Lett.*, 2017, **19**, 5288; (c) A. J. Reay, L. A. Hammarback, J. T. W. Bray, T. Sheridan, D. Turnbull, A. C. Whitwood and I. J. S. Fairlamb, *ACS Catal.*, 2017, **7**, 5174; (d) G. L. Tolnai, J. P. Brand and J. Waser, *Beilstein J. Org. Chem.*, 2016, **12**, 745; (e) T. J. Osberger, D. C. Rogness, J. T. Kohrt, A. F. Stepan and M. C. White, *Nature*, 2016, **537**, 214; (f) B. Mondal, B. Roy and U. Kazmaier, *J. Org. Chem.*, 2016, **81**, 11646; (g) E. Hernando, J. Villalva, Á. M. Martínez, I. Alonso, N. Rodríguez, R. Gómez Arrayás and J. C. Carretero, *ACS Catal.*, 2016, **6**, 6868; (h) X. Wu, D. Zhang, S. Zhou, F. Gao and H. Liu, *Chem. Commun.*, 2015, **51**, 12571; (i) O. Daugulis, J. Roane and L. D. Tran, *Acc. Chem. Res.*, 2015, **48**, 1053; (j) L. D. Tran and O. Daugulis, *Angew. Chem., Int. Ed.*, 2012, **51**, 5188; (k) H. Dong, C. Limberakis, S. Liras, D. Price and K. James, *Chem. Commun.*, 2012, **48**, 11644.
- 18 (a) Y. Hu and C. Wang, *ChemCatChem*, 2019, **11**, 1167; (b) W. Liu and L. Ackermann, *ACS Catal.*, 2016, **6**, 3743; (c) C. Wang, *Synlett*, 2013, **24**, 1606.
- 19 (a) S. A. Bernhard, A. Berger, J. H. Carter, E. Katchalski, M. Sela and Y. Shalitin, *J. Am. Chem. Soc.*, 1962, **84**, 2421; (b) D. W. Clayton, G. W. Kenner and R. C. Sheppard, *J. Chem. Soc.*, 1956, 371.
- 20 (a) L. Mendive-Tapia, J. Wang and M. Vendrell, *Pept. Sci.*, 2021, **113**, e24181; (b) C. Zhao, L. Mendive-Tapia and M. Vendrell, *Arch. Biochem. Biophys.*, 2019, **661**, 187; (c) C. Zhao, A. Fernandez, N. Avlonitis, G. V. Velde, M. Bradley, N. D. Read and M. Vendrell, *ACS Comb. Sci.*, 2016, **18**, 689; (d) L. Mendive-Tapia, C. Zhao, A. R. Akram, S. Preciado, F. Albericio, M. Lee, A. Serrels, N. Kielland, N. D. Read, R. Lavilla and M. Vendrell, *Nat. Commun.*, 2016, **7**, 10940.

